Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch. 2010;456:201–17.

Article  CAS  PubMed  Google Scholar 

World Health Organization (WHO) Classification of Soft Tissue and Bone Tumours. Lyon, France: International Agency for Research on Cancer (IARC), 2020.

Carvalho SD, Pissaloux D, Crombé A, Coindre JM, Le Loarer F. Pleomorphic sarcomas: the state of the art. Surg Pathol Clin. 2019;12:63–105.

Article  PubMed  Google Scholar 

Hornick JL. Subclassification of pleomorphic sarcomas: how and why should we care? Ann Diagn Pathol. 2018;37:118–24.

Article  PubMed  Google Scholar 

Toulmonde M, Lucchesi C, Verbeke S, et al. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine. 2020;62: 103131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen S, Huang W, Luo P, et al. Undifferentiated pleomorphic sarcoma: long-term follow-up from a large institution. Cancer Manag Res. 2019;11:10001–9.

Article  PubMed  PubMed Central  Google Scholar 

Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250–66.

Article  CAS  PubMed  Google Scholar 

Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006;48:51–62.

Article  CAS  PubMed  Google Scholar 

Wakely PE Jr. Cytopathology of myxofibrosarcoma: a study of 66 cases and literature review. J Am Soc Cytopathol. 2021;10:300–9.

Article  PubMed  Google Scholar 

Wang Z, Liu J, Han J, Yang Z, Wang Q. Analysis of prognostic factors of undifferentiated pleomorphic sarcoma and construction and validation of a prediction nomogram based on SEER database. Eur J Med Res. 2022;27:179.

Article  PubMed  PubMed Central  Google Scholar 

Gervais MK, Callegaro D, Gronchi A. The evolution of adjuvant/neoadjuvant trials for resectable localized sarcoma. J Surg Oncol. 2022;125:17–27.

Article  PubMed  Google Scholar 

Keung EZ, Tsai JW, Ali AM, et al. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018;7: e1385689.

Article  PubMed  Google Scholar 

Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859–68.

Article  CAS  PubMed  Google Scholar 

Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21:2719–25.

Article  PubMed  Google Scholar 

Vodanovich DA, Spelman T, May D, Slavin J, Choong PFM. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases. ANZ J Surg. 2019;89:1045–50.

Article  PubMed  Google Scholar 

Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5:60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346:1480–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74:2377–84.

Article  CAS  PubMed  Google Scholar 

Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14:3–13.

Article  CAS  PubMed  Google Scholar 

Hideyuki T, Yoko T, Daisuke M, Miharu K, Tohru M, Hiroshi M. Cell line individualization by STR multiplex system in the cell bank found cross-contamination between ECV304 and EJ-1/T24. Tissue Cult Res Commun. 1999;18:329–38.

Google Scholar 

Masters JR, Thomson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A. 2001;98:8012–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drexler HG, Dirks WG, MacLeod RA, Uphoff CC. False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal. Int J Cancer. 2017;140:1209–14.

Article  CAS  PubMed  Google Scholar 

Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akiyama T, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-PS1-C1: a novel cell line of pleomorphic sarcoma from a patient after neoadjuvant radiotherapy. Hum Cell. 2022;35:2011–9.

Article  CAS  PubMed  Google Scholar 

Vanni S, De Vita A, Gurrieri L, et al. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Ther Adv Med Oncol. 2022;14:17588359221093972.

Article  PubMed  PubMed Central  Google Scholar 

Lucarelli E, De Vita A, Bellotti C, et al. Modeling myxofibrosarcoma: where do we stand and what is missing? Cancers. 2023;15:5132.

Article  PubMed  PubMed Central  Google Scholar 

Li GZ, Okada T, Kim YM, et al. Rb and p53-deficient myxofibrosarcoma and undifferentiated pleomorphic sarcoma require Skp2 for survival. Cancer Res. 2020;80:2461–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kocakavuk E, Anderson KJ, Varn FS, et al. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nat Genet. 2021;53:1088–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008;68:2551–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garnock-Jones KP. Cobimetinib: first global approval. Drugs. 2015;75:1823–30.

Article  CAS  PubMed  Google Scholar 

Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76.

Article  PubMed  Google Scholar 

Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123:94–100.

Article  CAS